BPC-157 vs TB-500
Two of the most-hyped "healing" research peptides, compared honestly — what the animal data shows, what human evidence exists (almost none), and the regulatory reality.
Both are research chemicals with tissue-repair claims resting almost entirely on animal data and essentially no controlled human trials. Neither is approved for human use, and both are prohibited in sport. The honest comparison is not "which works better" but "both are unproven in humans, in different ways."
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide (gastric-juice derived) | Synthetic fragment related to Thymosin beta-4 |
| Regulatory status | Research chemical — not FDA-approved; listed in FDA compounding category 2 (may present significant safety risks) | Research chemical — not FDA-approved; listed in FDA compounding category 2 (may present significant safety risks) |
| Marketed claim | Tendon, ligament, and gut healing | Muscle, tendon, and soft-tissue recovery |
| Best evidence | Grade D — rodent studies of tendon/gut healing | Grade D — animal studies of tissue repair |
| Human trial evidence | Essentially none (controlled) | Essentially none (controlled) |
| Long-term human safety | Unknown (Grade U) | Unknown (Grade U) |
| WADA status | Prohibited (S0) | Prohibited (S2) |
| Product quality | Unregulated research-chemical supply | Unregulated research-chemical supply |
How to read this comparison
BPC-157 and TB-500 are almost always discussed together as an injury-recovery “stack,” and the marketing around both is far ahead of the science. Setting them side by side, the most important cells in the table are the same for both: human trial evidence — essentially none, and long-term safety — unknown.
The animal data are genuinely interesting. BPC-157 shows consistent tendon- and gut-healing effects across rodent models; TB-500 (and the parent molecule thymosin beta-4) shows tissue-repair activity. But Grade D preclinical evidence does not establish that either works — or is safe — in humans, and no amount of stacking two unproven compounds turns two D grades into a human result.
Both are sold through the unregulated research-chemical market, so purity and identity are uncertain on top of the evidence gap. Both are prohibited in sport. Neither is a legal therapeutic.
The regulatory record treats them the same way. FDA placed both in category 2 of its interim compounding policies — bulk drug substances that may present significant safety risks — citing immunogenicity risk for certain routes, peptide-related impurities, and inadequate safety data; for the thymosin beta-4 fragment sold as TB-500, FDA states it has identified no human exposure data at all. Both nominations were later withdrawn by their nominators, and FDA’s Pharmacy Compounding Advisory Committee took both compounds up again on 23 July 2026 for possible inclusion on the 503A Bulks List.
If you take one thing from this comparison, take this: the interesting question these compounds raise is whether they’d survive a real human trial — and until one is run, the honest grade for their headline claims stays at preclinical.
A note on "dose"
Any doses shown here are the amounts studied in trialsor the approved label schedule — not a recommendation, and not the same thing as a dose someone reports using online. See how we separate dose language.
References
- Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — tissue-healing review. Current Pharmaceutical Design (2018)
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2; lists both BPC-157 and Thymosin beta-4 fragment / TB-500)
- FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 considered for the 503A Bulks List)